Who We Are
Who We Are
Mission : Link between ‘patient suffering from undruggable disease’ and ‘hope for cure’
UPPTHERA was established in 2018 with the goal of developing innovative new medicines based on TPD (targeted protein degradation) technology. With a commitment to advancing the health and well-being of patients, our primary focus lies in researching and developing new medications aimed at offering hope to those who suffer from incurable diseases.
We specialize in identifying and validating diseases characterized by unmet medical needs for patients that could not be solved by existing drug paradigms using first-in-class drugs through the targeted protein degradation (TPD) modality. We are dedicated to conducting comprehensive research and development, from initial exploration to clinical trials. In addition, to address the challenges hindering the wider application of TPD in new drug development beyond the two known types of E3 ligases (CRBN and VHL), we have been actively working on developing platform technologies capable of identifying promising E3 ligases. To date, we have successfully identified a substantial number of Novel E3 ligase binders and developed the pipeline.
History
2024
- 04Selected for Super-gap Startup 1000+ Project
2023
- 07Attracted Series B-bridge 10 billion won investment
- 07Received the Merck Impact Award (2023 Korea Advance Biotech Grant Program)
- 06Selected for the New Research Talent Support Project
- 04Selected for the Leading Material Development Project of the KDDF National New Drug Development Project
2022
- 12Contracted Boryeong joint R&D and commercialization
- 09Contracted for selection at Daishin Securities listing
- 09Selected for the Non-clinical Project of the KDDF National New Drug Development Project
- 05Attracted Series B 28 billion won investment
- 04Transferred technology to Yuhan Corporation, contracted joint R&D
2021
- 09Received INNOBIZ certification (Technology innovation SME)
2020
- 10Selected for the Ministry of SMEs and Startups' Startup Growth Technology Development Project 4IR Project
- 07Attracted Series A 12.7 billion won investment
2019
- 10Selected as a Frontier Venture Business
- 06Founded an affiliated research center; TIPS selection and agreement
- 03Attracted Pre-series 2.6 billion won investment
2018
- 09Certificated for Venture Business
- 09Company foundation
Slogan : Synthesize possibilities, Degrade Despair
Core values
Autonomy
Guarantees autonomy to lead an active contribution to motivation and realize innovation
Plasticity and Dynamic
Reasonably, flexibly, and precisely cope with changing situations
Reliability
Derive data with clear grounds, with all decision-making based on the relevant data
Press Release
Transforming the lives of patients living with serious diseases
Technology
Differentiated technology platforms enablethe production of pipelines & novel E3L platforms in a persistent & organized manner
Pipeline
We develop degrader pipelines with a robust scientific rationale and a clear market goal
Novel E3L platform
We develop novel E3L platforms with distinct features and a robustscientific rationale, each of which has a potential to be superior to CRBN, VHL in a specific aspect
